Role of Uralyt-U in Patients With Hyperuricemia (NCT04352153) | Clinical Trial Compass
UnknownNot Applicable
Role of Uralyt-U in Patients With Hyperuricemia
China102 participantsStarted 2020-04-01
Plain-language summary
The purpose of the study is to provide a more direct and objective basis for the widespread use of potassium sodium hydrogen citrate granules in the treatment of uric acid stones.
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 18-70 years old, male, outpatient or inpatient;
* Acidic urinary stones
* Serum uric acid value ≥480 µmol / L;
* Other concomitant diseases (such as hypertension, hyperlipidemia, diabetes, etc.) are in a stable condition, and the dosage of other diseases is not changed during the test.
* eGFR≥30ml / min;
Exclusion Criteria:
* Pregnant or lactating women;
* Patients with acute or chronic renal failure (eGFR \<30ml / min);
* Patients with severe liver dysfunction (ALT, AST≥70 IU);
* In patients with uncontrolled hypertension, systolic blood pressure ≥160 and / or diastolic blood pressure ≥110mmHg;
* In uncontrolled diabetic patients, fasting blood glucose is\> 10mmol / L, and / or glycated hemoglobin is ≥9%;
* Patients that are taking atorvastatin, losartan, amlodipine, fenofibrate, pyrazinamide, tincture diuretics, thiazide diuretics, glucocorticoids, immunosuppressive agents and other drugs that affect uric acid excretion Drugs, those taking aspirin at a dose of\> 325mg / day;
* Cancer patients